{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:50:09Z","timestamp":1793134209682,"version":"4.5.0"},"reference-count":33,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: MR-guided radiation therapy (MRgRT) has rapidly evolved into an important treatment modality, with the Elekta Unity and ViewRay MRIdian systems being two major MR-linac platforms. Despite the shared concept of MRgRT, the two platforms elected different system designs that could potentially impact the dosimetric characteristics and quality of a treatment. In this study, we aim to perform a comparative dosimetric investigation between these two MR-linac systems in prostate and pancreas cancers. Methods: Dosimetric characteristics were evaluated by retrospectively re-creating 20 clinical prostate and pancreas cases originally treated on MRIdian using the Unity system, adhering to MIRAGE and SMART clinical trial constraints. Treatment plans were re-created with matching planning images, structures, beam geometry, and dose parameters. To ensure comparison consistency, all Unity treatment plans were normalized to match the target coverage of the MRIdian counterparts, and the organ-at-risk (OAR) dose was investigated. Results: Most OARs\u2019 dose-volume metrics showed no statistically significant differences. For prostate patients, Unity demonstrated lower rectum V36Gy (p = 0.0095), V38Gy (p = 0.0043), V40Gy (p = 0.0469), and lower left (p = 0.0137) and right femur V20Gy (p = 0.0020). For pancreas patients, Unity plans had a lower mean liver dose (p = 0.0371). All Unity plans had a Gamma passing rate &gt; 90%, confirming the clinical deliverability. Mean delivery times were 12.78 \u00b1 1.68 and 13.53 \u00b1 1.88 min for MRIdian and Unity prostate plans, respectively, and 14.58 \u00b1 2.78 and 17.40 \u00b1 3.77 min for MRIdian and Unity pancreas plans, respectively. Conclusions: Overall, comparable treatment quality and delivery times were observed between the two platforms.<\/jats:p>","DOI":"10.3390\/cancers17162708","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T13:18:14Z","timestamp":1755695894000},"page":"2708","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["MR-Guided Radiation Therapy for Prostate and Pancreas Cancer Treatment: A Dosimetric Study Across Two Major MR-Linac Platforms"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2695-4251","authenticated-orcid":false,"given":"Huiming","family":"Dong","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Pham","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1194-0148","authenticated-orcid":false,"given":"Michael V.","family":"Lauria","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiden","family":"Atienza","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4129-8258","authenticated-orcid":false,"given":"Brett","family":"Sloman","sequence":"additional","affiliation":[{"name":"Elekta USA, Atlanta, GA 30346, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Barry","sequence":"additional","affiliation":[{"name":"Elekta USA, Atlanta, GA 30346, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Davis","sequence":"additional","affiliation":[{"name":"Elekta USA, Atlanta, GA 30346, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6357-2610","authenticated-orcid":false,"given":"Michael","family":"Saracen","sequence":"additional","affiliation":[{"name":"Elekta USA, Atlanta, GA 30346, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Kishan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Raldow","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X. Sharon","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7638-9599","authenticated-orcid":false,"given":"Daniel","family":"Hyer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lamb","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Almansour, H., Afat, S., Fritz, V., Schick, F., Nachbar, M., Thorwarth, D., Zips, D., M\u00fcller, A.-C., Nikolaou, K., and Othman, A.E. (2021). Prospective Image Quality and Lesion Assessment in the Setting of MR-Guided Radiation Therapy of Prostate Cancer on an MR-Linac at 1.5 T: A Comparison to a Standard 3 T MRI. Cancers, 13.","DOI":"10.3390\/cancers13071533"},{"key":"ref_2","first-page":"68","article-title":"Prostate cancer\u2014Advantages and disadvantages of MR-guided RT","volume":"18","author":"Murray","year":"2019","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"20210800","DOI":"10.1259\/bjr.20210800","article-title":"MR-guided radiotherapy for prostate cancer: State of the art and future perspectives","volume":"95","author":"Sritharan","year":"2022","journal-title":"Br. J. Radiol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Stanescu, T., Shessel, A., Carpino-Rocca, C., Taylor, E., Semeniuk, O., Li, W., Barry, A., Lukovic, J., Dawson, L., and Hosni, A. (2022). MRI-Guided Online Adaptive Stereotactic Body Radiation Therapy of Liver and Pancreas Tumors on an MR-Linac System. Cancers, 14.","DOI":"10.3390\/cancers14030716"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1158\/0008-5472.CAN-16-2083","article-title":"Assessing Prostate Cancer Aggressiveness with Hyperpolarized Dual-Agent 3D Dynamic Imaging of Metabolism and Perfusion","volume":"77","author":"Chen","year":"2017","journal-title":"Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1593\/tlo.13838","article-title":"Variations of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Evaluation of Breast Cancer Therapy Response: A Multicenter Data Analysis Challenge","volume":"7","author":"Huang","year":"2014","journal-title":"Transl. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ijrobp.2018.06.012","article-title":"Quantitative Imaging for Radiation Oncology","volume":"102","author":"Thorwarth","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1158\/0008-5472.CAN-12-1085","article-title":"Hypoxia-Induced Gene Expression in Chemoradioresistant Cervical Cancer Revealed by Dynamic Contrast-Enhanced MRI","volume":"72","author":"Halle","year":"2012","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1593\/neo.81328","article-title":"Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations","volume":"11","author":"Padhani","year":"2009","journal-title":"Neoplasia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1102\/1470-7330.2010.9032","article-title":"Diffusion-weighted magnetic resonance imaging for tumour response assessment: Why, when and how?","volume":"10","author":"Afaq","year":"2010","journal-title":"Cancer Imaging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/bjc.2014.76","article-title":"Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography","volume":"110","author":"Li","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1593\/neo.101102","article-title":"Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research","volume":"13","author":"Kurhanewicz","year":"2011","journal-title":"Neoplasia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1158\/0008-5472.CAN-15-0840","article-title":"IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism","volume":"75","author":"Viswanath","year":"2015","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e697","DOI":"10.1002\/mp.14884","article-title":"Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294","volume":"48","author":"McGee","year":"2021","journal-title":"Med. Phys."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic Resonance Imaging\u2013Guided vs Computed Tomography\u2013Guided Stereotactic Body Radiotherapy for Prostate Cancer","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e14179","DOI":"10.1002\/acm2.14179","article-title":"The impact of margin reduction on radiation dose distribution of ultra-hypofractionated prostate radiotherapy utilizing a 1.5-T MR-Linac","volume":"25","author":"Onal","year":"2024","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"de Pooter, J., Billas, I., de Prez, L., Duane, S., Kapsch, R.-P., Karger, C.P., van Asselen, B., and Wolthaus, J. (2021). Reference dosimetry in MRI-linacs: Evaluation of available protocols and data to establish a Code of Practice. Phys. Med. Biol., 66.","DOI":"10.1088\/1361-6560\/ab9efe"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1088\/0031-9155\/53\/4\/006","article-title":"Magnetic-field-induced dose effects in MR-guided radiotherapy systems: Dependence on the magnetic field strength","volume":"53","author":"Raaijmakers","year":"2008","journal-title":"Phys. Med. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.eururo.2024.10.026","article-title":"Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial","volume":"87","author":"Kishan","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer","volume":"117","author":"Parikh","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.meddos.2018.02.005","article-title":"Monaco treatment planning system tools and optimization processes","volume":"43","author":"Clements","year":"2018","journal-title":"Med. Dosim."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1118\/1.597673","article-title":"3D electron dose calculation using a Voxel based Monte Carlo algorithm (VMC)","volume":"23","author":"Kawrakow","year":"1996","journal-title":"Med. Phys."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1118\/1.3539725","article-title":"GPUMCD: A new GPU-oriented Monte Carlo dose calculation platform","volume":"38","author":"Hissoiny","year":"2011","journal-title":"Med. Phys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1002\/mp.17021","article-title":"Technical note: Cryostat transmission characterization for MR linac\u2014Temporal stability, clinical impact and change implementation","volume":"51","author":"Jelen","year":"2024","journal-title":"Med. Phys."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1088\/0031-9155\/56\/10\/012","article-title":"Dose specification for radiation therapy: Dose to water or dose to medium?","volume":"56","author":"Ma","year":"2011","journal-title":"Phys. Med. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1002\/mp.12810","article-title":"Tolerance limits and methodologies for IMRT measurement-based verification QA: Recommendations of AAPM Task Group No. 218","volume":"45","author":"Miften","year":"2018","journal-title":"Med. Phys."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijrobp.2010.09.023","article-title":"Magnetic Resonance Lymphography\u2013Guided Selective High-Dose Lymph Node Irradiation in Prostate Cancer","volume":"82","author":"Meijer","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00066-004-1267-5","article-title":"The Incidence of Inclusion of the Sigmoid Colon and Small Bowel in the Planning Target Volume in Radiotherapy for Prostate Cancer","volume":"180","author":"Villeirs","year":"2004","journal-title":"Strahlenther. Onkol."},{"key":"ref_29","first-page":"100603","article-title":"Identifying predictors of on-table adaptation for pancreas stereotactic body radiotherapy (SBRT)","volume":"40","author":"Wu","year":"2023","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.radonc.2022.07.004","article-title":"First experimental demonstration of VMAT combined with MLC tracking for single and multi fraction lung SBRT on an MR-linac","volume":"174","author":"Uijtewaal","year":"2022","journal-title":"Radiother. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e14566","DOI":"10.1002\/acm2.14566","article-title":"Surrogate gating strategies for the Elekta Unity MR-Linac gating system","volume":"26","author":"Rusu","year":"2024","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.semradonc.2023.10.008","article-title":"Intrafraction Motion Management With MR-Guided Radiation Therapy","volume":"34","author":"Fast","year":"2024","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"109932","DOI":"10.1016\/j.radonc.2023.109932","article-title":"Gating and intrafraction drift correction on a 1.5 T MR-Linac: Clinical dosimetric benefits for upper abdominal tumors","volume":"189","author":"Grimbergen","year":"2023","journal-title":"Radiother. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/16\/2708\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:31:39Z","timestamp":1760034699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/16\/2708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":33,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["cancers17162708"],"URL":"https:\/\/doi.org\/10.3390\/cancers17162708","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]}}}